中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2009年
4期
299-301
,共3页
肝炎%乙型%慢性%阿德福韦酯%二环化合物
肝炎%乙型%慢性%阿德福韋酯%二環化閤物
간염%을형%만성%아덕복위지%이배화합물
Hepatitis B%chronic%Adefovir dipivoxil%Bieyclo compounds
目的 研究阿德福韦酯联合双环醇片治疗慢性乙型肝炎的疗效.方法 选择91例轻、中度慢性乙型肝炎患者随机分2组接受试验.试验组,46例,每日口服阿德福韦酯10 mg,同时每日服用双环醇片150 mg;对照组,45例,仅给予每日口服阿德福韦酯10 mg.2组均连续用药48周.观察治疗前后血清氨基转移酶水平及病毒学标志方面的改变.结果 2组血清氨基转移酶均得到明显下降,试验组更为显著(P<0.05).试验组HBV DNA阴转率(47.8%)显著高于对照组(31.1%),P<0.05,试验组HBeAg阴转率(32.6%)及HBeAg血清转换率(24.4%)虽高于对照组(19.6%、15.6%),但差异无统计学意义.2组均未发生明显的不良反应.结论 阿德福韦酯与双环醇片联合应用治疗慢性乙型肝炎在肝功能及病毒学方面取得较好疗效.
目的 研究阿德福韋酯聯閤雙環醇片治療慢性乙型肝炎的療效.方法 選擇91例輕、中度慢性乙型肝炎患者隨機分2組接受試驗.試驗組,46例,每日口服阿德福韋酯10 mg,同時每日服用雙環醇片150 mg;對照組,45例,僅給予每日口服阿德福韋酯10 mg.2組均連續用藥48週.觀察治療前後血清氨基轉移酶水平及病毒學標誌方麵的改變.結果 2組血清氨基轉移酶均得到明顯下降,試驗組更為顯著(P<0.05).試驗組HBV DNA陰轉率(47.8%)顯著高于對照組(31.1%),P<0.05,試驗組HBeAg陰轉率(32.6%)及HBeAg血清轉換率(24.4%)雖高于對照組(19.6%、15.6%),但差異無統計學意義.2組均未髮生明顯的不良反應.結論 阿德福韋酯與雙環醇片聯閤應用治療慢性乙型肝炎在肝功能及病毒學方麵取得較好療效.
목적 연구아덕복위지연합쌍배순편치료만성을형간염적료효.방법 선택91례경、중도만성을형간염환자수궤분2조접수시험.시험조,46례,매일구복아덕복위지10 mg,동시매일복용쌍배순편150 mg;대조조,45례,부급여매일구복아덕복위지10 mg.2조균련속용약48주.관찰치료전후혈청안기전이매수평급병독학표지방면적개변.결과 2조혈청안기전이매균득도명현하강,시험조경위현저(P<0.05).시험조HBV DNA음전솔(47.8%)현저고우대조조(31.1%),P<0.05,시험조HBeAg음전솔(32.6%)급HBeAg혈청전환솔(24.4%)수고우대조조(19.6%、15.6%),단차이무통계학의의.2조균미발생명현적불량반응.결론 아덕복위지여쌍배순편연합응용치료만성을형간염재간공능급병독학방면취득교호료효.
Objective To analyze the efficacy of adefovir dipivoxil combined with bieyclol in treatment of HBeAg-positive chronic viral hepatitis B (CHB). Methods A total ofgl patients with CHB were randomized into experimental group and control group to be treated. The patients in experimental group (46 samples) received adefovir dipivoxil orally 10 nag daily and bieyclol orally 150 mg daily for 48 weeks and those in control group (45 samples) received adefovir dipivoxil orally 10 mg daily alone for 48 weeks. The serum aminotransferace (ALT/ AST), HBV-DNA, HBeAg/antiHBe were observed before and after treatment. Results Compared with pre-treatment, the serum aminotransferace were all decreased obviously in two groups, the experimental group is better (P <0.05). HBVDNA negative conversion rate was significantly higher in experimental group than in the control group(47.8% vs. 31.1%, P < 0.05). There were nostatistically differrence between the two groups in the portion of HBeAg loss rate and HBeAg seroeonversion rate. There were no obvious adverse reaction in the study. Conclusion Adefovir dipivoxil combined with bicyclol is efective in the treatment of chronic hepatitis B.
